CHRISTOPHER RENZI: Open Payments
NPI 1285179390 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,116 in 215 payments from 39 companies in 2025. Trend: 2023 $3,150 · 2024 $4,127 · 2025 $4,116
Food & beverage: $4,116
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $695 |
| Novo Nordisk Inc | 24 | $476 |
| SHIELD THERAPEUTICS INC | 7 | $275 |
| AstraZeneca Pharmaceuticals LP | 13 | $274 |
| Aimmune Therapeutics, Inc. | 14 | $204 |
| PFIZER INC. | 15 | $188 |
| Lundbeck LLC | 7 | $176 |
| Lilly USA, LLC | 8 | $164 |
| Otsuka America Pharmaceutical, Inc. | 10 | $162 |
| Braeburn Inc. | 7 | $142 |
Products named: VRAYLAR, REXULTI, ACCRUFER, UBRELVY, NURTEC ODT, AIRSUPRA, BRIXADI, ZENPEP.
Industry payments across PA — which companies pay providers there.
